Test Discovered for Earlier Detection of Transplant Rejection
|
By LabMedica International staff writers Posted on 06 Apr 2017 |

Image: The NanoSight NS300 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
A method has been discovered that appears to provide earlier warning of organ transplant rejection compared to standard methods, and requires only a blood test rather than a more invasive and painful needle biopsy.
Approximately 30,000 organ transplants occur in the USA each year. However, depending on the organ type of the transplanted organs, between 20% and 50% fail within five years, most often because the recipient's immune system attacks, or "rejects," the donated organ.
Scientists at the Perelman School of Medicine at the University of Pennsylvania analyzed human blood and urine samples using a new method. The new method involves tiny, capsule-like structures known as exosomes, which normally are secreted from most types of cell. Precisely what exosomes evolved to do is not clear, but scientists know that these capsules contain proteins and other molecules from their mother cell that can influence the activities of neighboring cells. Like their mother cells, exosomes have protein markers on their surfaces, often called major histocompatibility complex (MHC) antigens that identify them to the immune system as part of the body. Just as donor and host cells usually differ in their MHC markers, so do donor and host exosomes.
Human pancreas was processed for islet isolation, and high-purity (>80%) islets were used for xenoislet transplantation. Islet isolation was performed and the islets were cultured in CMRL media supplemented with albumin, without any exogenous exosome contamination. Islet culture supernatant (20 mL) was obtained 24 to72 hours after isolation for exosome analysis. Exosomes were isolated from human islet culture supernatants by size exclusion limit gel chromatography along with ultracentrifugation. Exosomes were analyzed on the NanoSight NS300 (405 nm laser diode) on the light scatter mode for quantification and scatter distribution.
In an initial exploration of the transplant-exosome strategy in people, the team examined stored blood plasma samples from five recipients of transplanted islet cells in a clinical trial, and was able to detect donor exosomes in these samples following the transplants. They also found some preliminary evidence that their falling-exosome measure could be useful in predicting transplant rejection in people. For one patient who experienced a rejection of the transplanted islet cells, a steep drop in the level of donor exosomes was detectable in a blood sample taken six and a half months before the transplanted cells stopped working and the patient developed clinical signs of diabetes.
The scientists showed that they could isolate and detect donor-tissue exosomes in a different type of transplant: kidney transplant, currently the most common type of organ transplant. In this case, the team found that they could isolate and quantify donor-kidney exosomes not just in blood but also in urine, thus potentially enabling urine tests which are even less invasive than blood tests. Ali Naji, MD, PhD, a Professor of Surgery and senior author of the study said, “I believe that analyses of exosomes from transplanted organs will ultimately provide a very powerful and unprecedented ability to understand the conditional state of the organ as a whole.” The study was published on March 20, 2017, in the Journal of Clinical Investigation.
Approximately 30,000 organ transplants occur in the USA each year. However, depending on the organ type of the transplanted organs, between 20% and 50% fail within five years, most often because the recipient's immune system attacks, or "rejects," the donated organ.
Scientists at the Perelman School of Medicine at the University of Pennsylvania analyzed human blood and urine samples using a new method. The new method involves tiny, capsule-like structures known as exosomes, which normally are secreted from most types of cell. Precisely what exosomes evolved to do is not clear, but scientists know that these capsules contain proteins and other molecules from their mother cell that can influence the activities of neighboring cells. Like their mother cells, exosomes have protein markers on their surfaces, often called major histocompatibility complex (MHC) antigens that identify them to the immune system as part of the body. Just as donor and host cells usually differ in their MHC markers, so do donor and host exosomes.
Human pancreas was processed for islet isolation, and high-purity (>80%) islets were used for xenoislet transplantation. Islet isolation was performed and the islets were cultured in CMRL media supplemented with albumin, without any exogenous exosome contamination. Islet culture supernatant (20 mL) was obtained 24 to72 hours after isolation for exosome analysis. Exosomes were isolated from human islet culture supernatants by size exclusion limit gel chromatography along with ultracentrifugation. Exosomes were analyzed on the NanoSight NS300 (405 nm laser diode) on the light scatter mode for quantification and scatter distribution.
In an initial exploration of the transplant-exosome strategy in people, the team examined stored blood plasma samples from five recipients of transplanted islet cells in a clinical trial, and was able to detect donor exosomes in these samples following the transplants. They also found some preliminary evidence that their falling-exosome measure could be useful in predicting transplant rejection in people. For one patient who experienced a rejection of the transplanted islet cells, a steep drop in the level of donor exosomes was detectable in a blood sample taken six and a half months before the transplanted cells stopped working and the patient developed clinical signs of diabetes.
The scientists showed that they could isolate and detect donor-tissue exosomes in a different type of transplant: kidney transplant, currently the most common type of organ transplant. In this case, the team found that they could isolate and quantify donor-kidney exosomes not just in blood but also in urine, thus potentially enabling urine tests which are even less invasive than blood tests. Ali Naji, MD, PhD, a Professor of Surgery and senior author of the study said, “I believe that analyses of exosomes from transplanted organs will ultimately provide a very powerful and unprecedented ability to understand the conditional state of the organ as a whole.” The study was published on March 20, 2017, in the Journal of Clinical Investigation.
Latest Molecular Diagnostics News
- WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response
- FDA Clears Liquid Biopsy Test to Guide Earlier Breast Cancer Therapy Switch
- Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
- New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
- Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
- Liquid Biopsy Test Predicts Tissue of Origin in Cancer of Unknown Primary
- Study Identifies Genetic Marker Missing from Common Pharmacogenomic Panels
- Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes
- New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients
- New Automation Platform Standardizes DNA and RNA Extraction Across Clinical Workflows
- Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency
- New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
- Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
- Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
- Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
- Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read moreHematology
view channel
Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Mantle cell lymphoma can follow widely variable courses, from indolent disease to rapidly progressive cancer, complicating initial treatment selection. Many therapeutic decisions still rely on patient... Read more
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read morePathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read moreTechnology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read moreIndustry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more







